Department of Oncology/Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
Department of Oncology/Pathology, Karolinska Institutet, Stockholm, Sweden; Breast Center, Karolinska Comprehensive Cancer Center and Karolinska University Hospital, Stockholm, Sweden.
Crit Rev Oncol Hematol. 2023 Dec;192:104189. doi: 10.1016/j.critrevonc.2023.104189. Epub 2023 Oct 21.
BACKGROUND: The advent of targeted therapies signaled novel avenues for more optimal oncological outcomes. Antibody-drug conjugates (ADCs) have risen as a cornerstone of the ever-expanding targeted therapy era. The purpose of this systematic review is to delineate the rapidly evolving clinical landscape of ADCs for solid tumors. METHODS: A literature search was performed in Medline, Embase and Cochrane databases for phase II and III clinical trials. Outcomes of interest were the objective response rate, overall survival, progression-free survival and adverse events. RESULTS: A total of 92 clinical trials (76 phase II and 16 phase III) evaluated the efficacy and safety of ADCs for a plethora of solid tumors. Out of the 30 investigated ADCs, 8 have received approval by regulatory organizations for solid tumors. Currently, 52 phase III clinical trials for ADCs are ongoing. CONCLUSION: ADCs have shown promising results for several solid tumors and various cancer settings.
背景：靶向治疗的出现为获得更好的肿瘤学结果开辟了新途径。抗体药物偶联物（ADC）已成为不断扩展的靶向治疗时代的基石。本系统评价旨在描绘用于实体瘤的 ADC 的快速发展的临床前景。
方法：在 Medline、Embase 和 Cochrane 数据库中对 II 期和 III 期临床试验进行了文献检索。感兴趣的结果是客观缓解率、总生存期、无进展生存期和不良事件。
结果：共有 92 项临床试验（76 项 II 期和 16 项 III 期）评估了 ADC 对多种实体瘤的疗效和安全性。在 30 种研究的 ADC 中，有 8 种已获得监管机构对实体瘤的批准。目前，有 52 项 ADC 的 III 期临床试验正在进行中。
结论：ADC 已在多种实体瘤和多种癌症治疗环境中显示出良好的疗效。
Crit Rev Oncol Hematol. 2023-12
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2020-10-19
Hum Vaccin Immunother. 2025-12
NPJ Precis Oncol. 2025-1-2
Zotero 插件